Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more. Celgene's past success stemmed primarily from ...

As part of a new research deal with Celgene Corp., a startup with intriguing technology that could someday enable personalized medicine by letting doctors test different cancer drugs in a patient’s ...

US biotech firm Celgene on Monday announced a deal to acquire the bio-pharmaceutical company Juno Therapeutics for $9 billion or $87 per share. The Seattle-based Juno is a leader in developing ...

Celgene, on the same day it announced it would be acquired by Bristol-Myers Squibb, raised the price of its top cancer treatment Revlimid by 3.5 percent, according to Bloomberg. 1. Celgene raised the ...

Celgene Corp. of Summit today announced that its lung cancer drug, Amrubicin, has been granted orphan drug designation by the U.S. Food and Drug Administration.Celgene Corp. (Nasdaq: CELG) of Summit ...

Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...

The Food and Drug Administration on Tuesday approved Celgene Corp.’s cancer drug for use with a companion diagnostic test developed by Abbott Laboratories. Idhifa is used to treat adults with relapsed ...

The post Why Do Americans Pay More for Prescription Drugs? appeared first on ProPublica.

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

NEW YORK, Dec 1 (Reuters) - A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal ...

Avila Therapeutics Inc., which raised $51 million in venture capital to develop covalent drugs that are designed to silence disease-causing proteins, said it has agreed to be acquired by Celgene Corp.